Search

Displaying results 1011 - 1020 of 5383 in total
  1. Drug

    Sulfur hexafluoride

    go.drugbank.com/drugs/DB11104
    ApprovedInvestigational

    Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border

  2. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is

  3. Drug

    Mephentermine

    go.drugbank.com/drugs/DB01365
    ApprovedWithdrawn

    Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence.

  4. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  5. Drug

    Aztreonam

    go.drugbank.com/drugs/DB00355
    ApprovedInvestigational

    A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinf...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    generally safe[L41790]; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use … [L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left

  7. Drug

    Valganciclovir

    go.drugbank.com/drugs/DB01610
    ApprovedInvestigational

    After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. … Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.

  9. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.

  10. Drug

    Raltegravir

    go.drugbank.com/drugs/DB06817
    ApprovedInvestigational

    Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use